165 related articles for article (PubMed ID: 15378729)
1. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
Sinha SC; Li LS; Watanabe S; Kaltgrad E; Tanaka F; Rader C; Lerner RA; Barbas CF
Chemistry; 2004 Oct; 10(21):5467-72. PubMed ID: 15378729
[TBL] [Abstract][Full Text] [Related]
2. Prodrug activation gated by a molecular "OR" logic trigger.
Amir RJ; Popkov M; Lerner RA; Barbas CF; Shabat D
Angew Chem Int Ed Engl; 2005 Jul; 44(28):4378-81. PubMed ID: 15942963
[No Abstract] [Full Text] [Related]
3. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
5. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
[TBL] [Abstract][Full Text] [Related]
6. A doxorubicin prodrug activated by the staudinger reaction.
van Brakel R; Vulders RC; Bokdam RJ; Grüll H; Robillard MS
Bioconjug Chem; 2008 Mar; 19(3):714-8. PubMed ID: 18271515
[TBL] [Abstract][Full Text] [Related]
7. Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab.
Sinha SC; Li LS; Miller GP; Dutta S; Rader C; Lerner RA
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3095-9. PubMed ID: 14981258
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.
Shamis M; Lode HN; Shabat D
J Am Chem Soc; 2004 Feb; 126(6):1726-31. PubMed ID: 14871103
[TBL] [Abstract][Full Text] [Related]
9. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
Hu Z; Jiang X; Albright CF; Graciani N; Yue E; Zhang M; Zhang SY; Bruckner R; Diamond M; Dowling R; Rafalski M; Yeleswaram S; Trainor GL; Seitz SP; Han W
Bioorg Med Chem Lett; 2010 Feb; 20(3):853-6. PubMed ID: 20060717
[TBL] [Abstract][Full Text] [Related]
10. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective aldol cyclodehydrations catalyzed by antibody 38C2.
List B; Lerner RA; Barbas CF
Org Lett; 1999 Jul; 1(1):59-61. PubMed ID: 10822533
[TBL] [Abstract][Full Text] [Related]
12. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
13. Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity.
Zhang A; Yao L; An M
Chem Commun (Camb); 2017 Nov; 53(95):12826-12829. PubMed ID: 29143021
[TBL] [Abstract][Full Text] [Related]
14. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
Nudelman A; Levovich I; Cutts SM; Phillips DR; Rephaeli A
J Med Chem; 2005 Feb; 48(4):1042-54. PubMed ID: 15715472
[TBL] [Abstract][Full Text] [Related]
15. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
16. Intensely cytotoxic anthracycline prodrugs: glucuronides.
Bakina E; Wu Z; Rosenblum M; Farquhar D
J Med Chem; 1997 Dec; 40(25):4013-8. PubMed ID: 9406592
[TBL] [Abstract][Full Text] [Related]
17. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of HIV-1 entry with a chemically programmed antibody aided by an efficient organocatalytic synthesis.
Gavrilyuk J; Uehara H; Otsubo N; Hessell A; Burton DR; Barbas CF
Chembiochem; 2010 Oct; 11(15):2113-8. PubMed ID: 20845359
[No Abstract] [Full Text] [Related]
19. Prodrugs of anthracycline antibiotics suited for tumor-specific activation.
Azoulay M; Florent JC; Monneret C; Gesson JP; Jacquesy JC; Tillequin F; Koch M; Bosslet K; Czech J; Hoffman D
Anticancer Drug Des; 1995 Sep; 10(6):441-50. PubMed ID: 7575986
[TBL] [Abstract][Full Text] [Related]
20. Poly (ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: design, synthesis and biological evaluation.
Zhao YJ; Wei W; Su ZG; Ma GH
Int J Pharm; 2009 Sep; 379(1):90-9. PubMed ID: 19540322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
